Cargando…

SARS-CoV-2 seroprevalence among children in Latvia: A cross-sectional study

Coronavirus disease 2019 (COVID-19) is a major global health concern. In contrast to adults, the course of the disease has been observed to be mild or even asymptomatic in children. It is therefore both clinically and epidemiologically important to measure the seroprevalence in children and adolesce...

Descripción completa

Detalles Bibliográficos
Autores principales: Sapronova, Krista, Kaķe, Rūta, Pavāre, Jana, Grāvele, Dagne, Šēla, Ivita, Ērgle, Estere, Isarova, Dana, Grīnberga, Zanda, Zavadska, Dace
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9907906/
https://www.ncbi.nlm.nih.gov/pubmed/36820593
http://dx.doi.org/10.1097/MD.0000000000032795
_version_ 1784884270029864960
author Sapronova, Krista
Kaķe, Rūta
Pavāre, Jana
Grāvele, Dagne
Šēla, Ivita
Ērgle, Estere
Isarova, Dana
Grīnberga, Zanda
Zavadska, Dace
author_facet Sapronova, Krista
Kaķe, Rūta
Pavāre, Jana
Grāvele, Dagne
Šēla, Ivita
Ērgle, Estere
Isarova, Dana
Grīnberga, Zanda
Zavadska, Dace
author_sort Sapronova, Krista
collection PubMed
description Coronavirus disease 2019 (COVID-19) is a major global health concern. In contrast to adults, the course of the disease has been observed to be mild or even asymptomatic in children. It is therefore both clinically and epidemiologically important to measure the seroprevalence in children and adolescents to discern the overall morbidity of the disease and to compare these findings with similar data collected globally. We conducted a cross-sectional study between March and July of 2022 at the Children Clinical University Hospital in Riga, Latvia, to evaluate the seroprevalence of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Participants aged 0 to 18 years were enrolled during hospitalization for reasons other than COVID-19. The levels of SARS-CoV-2 spike protein and nucleocapsid antibodies were measured in blood samples. The possibility of transplacental antibody transport was evaluated by directly interviewing the mothers of participants aged 18 months and younger. Various demographic and epidemiological risk factors and their association with seroprevalence were analyzed. Positive SARS-CoV-2 nucleocapsid antibodies were designated the main criterion for seropositivity. Of 200 enrolled children, 173 were found to be seropositive, resulting in an overall seroprevalence of 86.5%. The highest seroprevalence was detected in children and adolescents aged 12 to 18 years. With the progression of the COVID-19 pandemic, the seroprevalence in children has increased significantly. We found that almost 1-third of seropositive children in our study population were unaware of being previously infected with SARS-CoV-2 due to an asymptomatic course of the disease. Our study findings pertaining to high seropositivity among children and adolescents might be beneficial for public authorities to adapt epidemiological strategies and prevention measures. The high seroprevalence rate reported here and in many other populations around the world suggests that COVID-19 will likely become one of the many seasonal viral infections.
format Online
Article
Text
id pubmed-9907906
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-99079062023-02-10 SARS-CoV-2 seroprevalence among children in Latvia: A cross-sectional study Sapronova, Krista Kaķe, Rūta Pavāre, Jana Grāvele, Dagne Šēla, Ivita Ērgle, Estere Isarova, Dana Grīnberga, Zanda Zavadska, Dace Medicine (Baltimore) 4900 Coronavirus disease 2019 (COVID-19) is a major global health concern. In contrast to adults, the course of the disease has been observed to be mild or even asymptomatic in children. It is therefore both clinically and epidemiologically important to measure the seroprevalence in children and adolescents to discern the overall morbidity of the disease and to compare these findings with similar data collected globally. We conducted a cross-sectional study between March and July of 2022 at the Children Clinical University Hospital in Riga, Latvia, to evaluate the seroprevalence of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Participants aged 0 to 18 years were enrolled during hospitalization for reasons other than COVID-19. The levels of SARS-CoV-2 spike protein and nucleocapsid antibodies were measured in blood samples. The possibility of transplacental antibody transport was evaluated by directly interviewing the mothers of participants aged 18 months and younger. Various demographic and epidemiological risk factors and their association with seroprevalence were analyzed. Positive SARS-CoV-2 nucleocapsid antibodies were designated the main criterion for seropositivity. Of 200 enrolled children, 173 were found to be seropositive, resulting in an overall seroprevalence of 86.5%. The highest seroprevalence was detected in children and adolescents aged 12 to 18 years. With the progression of the COVID-19 pandemic, the seroprevalence in children has increased significantly. We found that almost 1-third of seropositive children in our study population were unaware of being previously infected with SARS-CoV-2 due to an asymptomatic course of the disease. Our study findings pertaining to high seropositivity among children and adolescents might be beneficial for public authorities to adapt epidemiological strategies and prevention measures. The high seroprevalence rate reported here and in many other populations around the world suggests that COVID-19 will likely become one of the many seasonal viral infections. Lippincott Williams & Wilkins 2023-02-10 /pmc/articles/PMC9907906/ /pubmed/36820593 http://dx.doi.org/10.1097/MD.0000000000032795 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial License 4.0 (CCBY-NC) (https://creativecommons.org/licenses/by-nc/4.0/) , where it is permissible to download, share, remix, transform, and buildup the work provided it is properly cited. The work cannot be used commercially without permission from the journal.
spellingShingle 4900
Sapronova, Krista
Kaķe, Rūta
Pavāre, Jana
Grāvele, Dagne
Šēla, Ivita
Ērgle, Estere
Isarova, Dana
Grīnberga, Zanda
Zavadska, Dace
SARS-CoV-2 seroprevalence among children in Latvia: A cross-sectional study
title SARS-CoV-2 seroprevalence among children in Latvia: A cross-sectional study
title_full SARS-CoV-2 seroprevalence among children in Latvia: A cross-sectional study
title_fullStr SARS-CoV-2 seroprevalence among children in Latvia: A cross-sectional study
title_full_unstemmed SARS-CoV-2 seroprevalence among children in Latvia: A cross-sectional study
title_short SARS-CoV-2 seroprevalence among children in Latvia: A cross-sectional study
title_sort sars-cov-2 seroprevalence among children in latvia: a cross-sectional study
topic 4900
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9907906/
https://www.ncbi.nlm.nih.gov/pubmed/36820593
http://dx.doi.org/10.1097/MD.0000000000032795
work_keys_str_mv AT sapronovakrista sarscov2seroprevalenceamongchildreninlatviaacrosssectionalstudy
AT kakeruta sarscov2seroprevalenceamongchildreninlatviaacrosssectionalstudy
AT pavarejana sarscov2seroprevalenceamongchildreninlatviaacrosssectionalstudy
AT graveledagne sarscov2seroprevalenceamongchildreninlatviaacrosssectionalstudy
AT selaivita sarscov2seroprevalenceamongchildreninlatviaacrosssectionalstudy
AT ergleestere sarscov2seroprevalenceamongchildreninlatviaacrosssectionalstudy
AT isarovadana sarscov2seroprevalenceamongchildreninlatviaacrosssectionalstudy
AT grinbergazanda sarscov2seroprevalenceamongchildreninlatviaacrosssectionalstudy
AT zavadskadace sarscov2seroprevalenceamongchildreninlatviaacrosssectionalstudy